This company has been marked as potentially delisted and may not be actively trading.

Hologic (HOLX) Financials

Annual Income Statements for Hologic

This table shows Hologic's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	9/26/2015	9/24/2016	9/30/2017	9/29/2018	9/28/2019	9/26/2020	9/25/2021	9/24/2022	9/30/2023	9/28/2024	9/27/2025
Net Income / (Loss) Attributable to Common Shareholders	132	331	-	-111	-204	1,115	1,872	1,302	456	790	566
Consolidated Net Income / (Loss)	132	331	756	-111	-204	1,111	1,870	1,302	456	790	566
Net Income / (Loss) Continuing Operations	132	331	-	-111	-204	1,111	1,870	1,302	456	790	566
Total Pre-Tax Income	177	415	1,231	-419	-258	1,002	2,361	1,588	676	865	681
Total Operating Income	455	549	1,370	-238	-124	1,105	2,480	1,640	668	883	714
Total Gross Profit	1,433	1,563	-	1,697	1,171	2,228	3,796	2,997	2,072	2,228	2,118
Total Revenue	2,705	2,833	-	3,218	3,367	3,776	5,632	4,863	4,030	4,030	4,101
Operating Revenue	2,705	2,833	3,059	3,218	3,367	3,776	5,632	4,863	4,030	4,030	4,101
Total Cost of Revenue	1,272	1,066	-	1,521	2,196	1,549	1,837	1,865	1,959	1,803	1,983
Operating Cost of Revenue	1,272	1,066	1,203	1,521	2,196	1,549	1,837	1,865	1,959	1,803	1,983
Total Operating Expenses	978	1,218	-	1,935	1,295	1,123	1,316	1,357	1,403	1,345	1,404
Selling, General & Admin Expense	261	267	343	366	332	356	433	408	392	409	449
Marketing Expense	363	415	499	545	565	485	561	630	595	585	621
Research & Development Expense	215	232	233	219	232	223	276	283	294	273	248
Amortization Expense	110	293	297	59	52	40	42	45	28	29	14
Other Operating Expenses / (Income)	-	-	-	-	0.00	0.30	-6.70	-40	-15	1.70	0.00
Impairment Charge	-	0.00	0.00	732	107	4.40	0.00	28	44	5.60	43
Restructuring Charge	29	11	13	14	6.60	15	9.30	2.40	12	41	29
Other Special Charges / (Income)	0.00	0.00	-900	-	-	-	0.00	0.00	52	0.00	0.00
Total Other Income / (Expense), net	-278	-133	-	-181	-134	-103	-119	-52	7.70	-18	-33
Interest Expense	268	161	156	195	142	117	115	96	111	122	117
Interest & Investment Income	1.30	0.70	3.80	6.30	4.60	4.30	1.40	13	121	109	74
Other Income / (Expense), net	-11	27	13	7.60	3.10	9.10	-5.40	31	-1.70	-4.10	9.60
Income Tax Expense	46	85	475	-307	-54	-109	491	286	220	76	116
Basic Earnings per Share	$0.47	$1.18	$2.70	($0.40)	($0.76)	$4.24	$7.28	$5.18	$1.85	$3.35	$2.50
Weighted Average Basic Shares Outstanding	280.57M	280.21M	559.62M	275.11M	269.41M	262.73M	257.05M	251.53M	246.77M	235.72M	226.16M
Diluted Earnings per Share	$0.45	$1.16	$2.64	($0.40)	($0.76)	$4.21	$7.21	$5.13	$1.83	$3.32	$2.49
Weighted Average Diluted Shares Outstanding	289.54M	286.16M	565.46M	275.11M	269.41M	264.61M	259.71M	253.85M	248.83M	237.55M	227.57M
Weighted Average Basic & Diluted Shares Outstanding	280M	280.30M	279.81M	289.21M	268.15M	257.01M	251.42M	245.83M	240.00M	226.94M	222.91M

This table shows Hologic's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	7/1/2023	9/30/2023	12/30/2023	3/30/2024	6/29/2024	9/28/2024	12/28/2024	3/29/2025	6/28/2025	9/27/2025	12/27/2025
Net Income / (Loss) Attributable to Common Shareholders	-41	91	247	170	195	179	201	-17	195	187	179
Consolidated Net Income / (Loss)	-41	91	247	170	195	179	201	-17	195	187	179
Net Income / (Loss) Continuing Operations	-41	91	247	170	195	179	201	-17	195	187	179
Total Pre-Tax Income	12	146	191	212	241	222	248	-29	235	227	230
Total Operating Income	1.40	133	198	210	244	230	230	-7.00	255	237	237
Total Gross Profit	368	500	568	542	560	558	581	377	577	584	586
Total Revenue	984	945	1,013	1,018	1,011	988	1,022	1,005	1,024	1,050	1,048
Operating Revenue	984	945	1,013	1,018	1,011	988	1,022	1,005	1,024	1,050	1,048
Total Cost of Revenue	617	445	446	476	451	430	441	628	447	466	461
Operating Cost of Revenue	617	445	446	476	451	430	441	628	447	466	461
Total Operating Expenses	366	368	369	332	316	328	351	384	322	347	349
Selling, General & Admin Expense	90	93	112	100	94	103	116	120	99	115	128
Marketing Expense	150	140	149	144	146	146	166	154	152	148	155
Research & Development Expense	73	73	67	75	64	67	60	62	61	65	61
Amortization Expense	7.10	6.30	13	5.70	5.30	4.90	4.70	3.80	3.00	2.90	2.30
Restructuring Charge	2.10	7.00	23	6.10	6.20	6.30	3.90	7.40	6.30	11	3.90
Total Other Income / (Expense), net	11	13	-6.90	1.10	-3.30	-8.40	18	-22	-20	-9.70	-7.30
Interest Expense	28	28	26	32	32	32	31	29	29	29	28
Interest & Investment Income	33	36	28	24	28	28	24	15	16	19	20
Other Income / (Expense), net	5.90	5.30	-8.80	9.40	0.20	-4.90	24	-7.30	-7.10	-	0.60
Income Tax Expense	53	55	-55	42	46	43	47	-11	40	40	51
Basic Earnings per Share	($0.16)	$0.37	$1.03	$0.72	$0.83	$0.77	$0.87	($0.08)	$0.87	$0.84	$0.80
Weighted Average Basic Shares Outstanding	246.91M	246.77M	238.63M	235.89M	234.60M	235.72M	230.28M	225.77M	224.32M	226.16M	224.41M
Diluted Earnings per Share	($0.16)	$0.37	$1.03	$0.72	$0.82	$0.75	$0.87	($0.08)	$0.86	$0.84	$0.79
Weighted Average Diluted Shares Outstanding	246.91M	248.83M	240.21M	237.56M	236.47M	237.55M	232.11M	225.77M	225.46M	227.57M	225.88M
Weighted Average Basic & Diluted Shares Outstanding	244.94M	240.00M	234.73M	233.38M	232.27M	226.94M	224.39M	222.85M	222.42M	222.91M	223.24M

This table details how cash moves in and out of Hologic's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	9/26/2015	9/24/2016	9/30/2017	9/29/2018	9/28/2019	9/26/2020	9/25/2021	9/24/2022	9/30/2023	9/28/2024	9/27/2025
Net Change in Cash & Equivalents	-245	57	-7.80	133	-65	99	469	1,169	416	-596	-201
Net Cash From Operating Activities	797	798	8.30	733	650	897	2,330	2,126	1,051	1,285	1,057
Net Cash From Continuing Operating Activities	797	798	8.30	733	650	897	2,330	2,126	1,051	1,285	1,057
Net Income / (Loss) Continuing Operations	132	331	756	-111	-204	1,111	1,870	1,302	456	790	566
Consolidated Net Income / (Loss)	132	331	756	-111	-204	1,111	1,870	1,302	456	790	566
Depreciation Expense	82	82	90	102	93	83	88	89	90	99	109
Amortization Expense	474	435	409	379	371	293	319	341	234	210	191
Non-Cash Adjustments To Reconcile Net Income	160	49	-785	867	782	141	118	145	384	173	354
Changes in Operating Assets and Liabilities, net	-50	-99	-460	-504	-392	-730	-64	249	-112	14	-162
Net Cash From Investing Activities	-86	-68	286	-195	-281	-142	-1,330	-206	-152	-781	-483
Net Cash From Continuing Investing Activities	-86	-68	286	-195	-281	-142	-1,330	-206	-152	-781	-483
Purchase of Property, Plant & Equipment	-89	-95	-108	-106	-109	-156	-178	-127	-150	-130	-137
Acquisitions	0.00	0.00	-1,558	-77	-133	-119	-1,171	-159	-5.00	-307	-337
Purchase of Investments	-	0.00	0.00	-6.00	-	-	-	0.00	-10	-310	-182
Divestitures	0.00	0.00	1,865	0.00	0.00	139	-	0.00	0.00	-31	0.00
Sale and/or Maturity of Investments	10	36	87	-	-	-	-	-	0.00	0.00	176
Other Investing Activities, net	-6.70	-10	-0.60	-7.10	-38	-5.10	19	80	13	-2.00	-2.90
Net Cash From Financing Activities	-947	-671	-309	-405	-432	-660	-530	-756	-483	-1,109	-777
Net Cash From Continuing Financing Activities	-947	-671	-309	-405	-432	-660	-530	-756	-483	-1,109	-777
Repayment of Debt	-3,844	-693	-530	-4,176	-2,279	-796	-431	-1,700	-15	-288	-37
Repurchase of Common Equity	0.00	-250	-200	-276	-200	-654	-410	-542	-475	-835	-753
Issuance of Common Equity	70	39	49	33	50	66	51	34	43	38	39
Other Financing Activities, net	-26	-16	-22	-20	-23	-40	-52	-39	-36	-24	-27
Effect of Exchange Rate Changes	-8.10	-2.00	7.30	-	-	4.10	-1.70	-	-	8.90	2.10

This table details how cash moves in and out of Hologic's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	7/1/2023	9/30/2023	12/30/2023	3/30/2024	6/29/2024	9/28/2024	12/28/2024	3/29/2025	6/28/2025	9/27/2025	12/27/2025
Net Change in Cash & Equivalents	183	-9.30	-824	248	259	-279	-378	-353	306	224	209
Net Cash From Operating Activities	333	259	220	292	406	367	189	169	343	355	230
Net Cash From Continuing Operating Activities	333	259	220	292	406	367	189	169	343	355	230
Net Income / (Loss) Continuing Operations	-41	91	247	170	195	179	201	-17	195	187	179
Consolidated Net Income / (Loss)	-41	91	247	170	195	179	201	-17	195	187	179
Depreciation Expense	22	23	30	23	23	24	23	24	26	35	26
Amortization Expense	59	53	59	51	50	51	51	52	44	44	43
Non-Cash Adjustments To Reconcile Net Income	242	69	61	48	38	27	11	270	27	46	34
Changes in Operating Assets and Liabilities, net	50	24	-175	0.70	101	87	-97	-159	51	43	-52
Net Cash From Investing Activities	-39	-56	-104	-39	-43	-596	-22	-324	-4.30	-132	-12
Net Cash From Continuing Investing Activities	-39	-56	-104	-39	-43	-596	-22	-324	-4.30	-132	-12
Purchase of Property, Plant & Equipment	-37	-53	-38	-28	-34	-30	-32	-40	-35	-30	-35
Acquisitions	-	-5.00	0.00	-	-	-297	-15	-323	1.30	-	0.00
Purchase of Investments	-	-	-35	-	-3.00	-268	-6.00	-9.00	-18	-149	-24
Sale and/or Maturity of Investments	-	-	0.00	-	-	-	32	48	48	48	48
Other Investing Activities, net	-2.20	1.50	-0.40	-5.50	4.30	-0.40	-1.00	-0.60	-0.80	-0.80	-1.00
Net Cash From Financing Activities	-110	-211	-944	-4.20	-104	-57	-537	-202	-40	1.60	-11
Net Cash From Continuing Financing Activities	-110	-211	-944	-4.20	-104	-57	-537	-202	-40	1.60	-11
Repayment of Debt	-3.80	-3.70	-259	-9.40	-9.30	-9.40	-9.40	-9.40	-9.30	-8.40	0.00
Repurchase of Common Equity	-114	-211	-677	-	-100	-58	-517	-200	-36	-	0.00
Issuance of Common Equity	9.30	5.30	9.50	8.90	6.80	13	12	8.70	6.80	11	8.30
Other Financing Activities, net	-1.50	-1.00	-17	-3.70	-1.30	-1.70	-23	-1.00	-2.00	-1.10	-19
Effect of Exchange Rate Changes	-1.70	-	4.40	-1.80	-0.30	6.60	-8.40	-	-	-	1.40

This table presents Hologic's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	9/26/2015	9/24/2016	9/30/2017	9/29/2018	9/28/2019	9/26/2020	9/25/2021	9/24/2022	9/30/2023	9/28/2024	9/27/2025
Total Assets	7,643	7,317	7,980	7,231	6,442	7,196	8,920	9,071	9,139	9,156	9,015
Total Current Assets	1,266	1,327	1,479	1,723	1,793	2,222	3,169	3,862	4,185	3,823	3,668
Cash & Equivalents	491	548	541	667	602	701	0.00	0.00	2,723	2,160	1,960
Short-Term Investments	-	-	-	-	-	-	-	-	0.00	173	243
Accounts Receivable	416	447	534	579	649	1,029	943	618	626	600	601
Inventories, net	283	275	332	384	445	395	501	624	618	680	679
Prepaid Expenses	33	40	51	62	63	59	529	232	175	156	152
Current Deferred & Refundable Income Taxes	41	17	22	32	35	39	26	49	32	53	33
Plant, Property, & Equipment, net	457	460	473	478	471	492	565	482	517	538	560
Total Noncurrent Assets	5,920	5,530	6,028	5,030	4,178	4,482	5,187	4,728	4,438	4,795	4,787
Goodwill	2,808	2,803	3,171	2,533	2,564	2,658	3,282	3,237	3,281	3,443	3,641
Intangible Assets	3,023	2,643	2,772	2,399	1,460	1,308	1,659	1,281	889	845	589
Other Noncurrent Operating Assets	88	84	85	98	155	517	246	211	268	411	558
Total Liabilities & Shareholders' Equity	7,643	7,317	7,980	7,231	6,442	7,196	8,920	9,071	9,139	9,156	9,015
Total Liabilities	5,563	5,174	5,195	4,802	4,326	4,489	4,701	4,195	4,122	4,026	3,967
Total Current Liabilities	943	902	1,866	1,403	1,070	1,239	1,327	938	1,207	1,037	977
Short-Term Debt	391	296	1,152	601	273	325	313	15	287	38	2.90
Accounts Payable	117	157	167	192	187	179	216	198	175	204	193
Accrued Expenses	272	288	375	436	431	548	596	535	535	580	578
Current Deferred Revenue	163	161	171	173	180	186	198	187	199	213	200
Other Current Liabilities	-	-	-	-	-	1.90	3.70	3.20	3.10	3.30	3.50
Total Noncurrent Liabilities	4,620	4,272	3,329	3,400	3,256	3,249	3,375	3,257	2,915	2,989	2,990
Long-Term Debt	3,221	3,049	2,172	2,705	2,784	2,714	2,712	2,808	2,531	2,497	2,505
Capital Lease Obligations	-	0.00	23	21	19	-	23	18	15	12	9.00
Noncurrent Deferred Revenue	20	16	21	18	16	13	20	9.40	14	14	12
Noncurrent Deferred & Payable Income Tax Liabilities	1,178	983	974	498	275	202	251	91	20	59	43
Other Noncurrent Operating Liabilities	201	225	140	158	162	321	369	331	335	406	420
Total Equity & Noncontrolling Interests	2,079	2,143	2,785	2,429	2,116	2,707	4,219	4,876	5,017	5,130	5,048
Total Preferred & Common Equity	2,079	2,143	2,785	2,429	2,116	2,705	4,219	4,876	5,017	5,130	5,048
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	2,079	2,143	2,785	2,429	2,116	2,705	4,219	4,876	5,017	5,130	5,048
Common Stock	5,563	5,563	5,634	5,674	5,773	5,908	5,969	6,046	6,144	6,247	6,348
Retained Earnings	-3,469	-3,138	-2,383	-2,494	-2,689	-1,573	298	1,600	2,056	2,846	3,412
Treasury Stock	0.00	-250	-450	-726	-926	-1,580	-1,989	-2,532	-3,036	-3,852	-4,611
Accumulated Other Comprehensive Income / (Loss)	-15	-32	-16	-26	-42	-50	-59	-238	-148	-112	-101

This table presents Hologic's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	4/1/2023	7/1/2023	9/30/2023	12/30/2023	3/30/2024	6/29/2024	9/28/2024	12/28/2024	3/29/2025	6/28/2025	12/27/2025
Total Assets	9,449	9,338	9,139	8,470	8,714	8,890	9,156	8,729	8,545	8,806	9,181
Total Current Assets	4,211	4,339	4,185	3,494	3,789	3,997	3,823	3,494	3,209	3,421	3,843
Cash & Equivalents	2,582	2,765	2,723	1,932	2,180	2,439	2,160	1,782	1,430	1,735	2,168
Short-Term Investments	-	-	0.00	-	-	-	173	191	192	144	197
Accounts Receivable	714	687	626	671	647	629	600	631	644	609	584
Inventories, net	688	680	618	634	649	666	680	707	717	714	689
Prepaid Expenses	228	207	175	258	312	158	156	158	166	164	176
Current Deferred & Refundable Income Taxes	-	-	32	-	-	106	53	24	61	55	30
Plant, Property, & Equipment, net	498	493	517	527	525	529	538	537	556	571	568
Total Noncurrent Assets	4,739	4,505	4,438	4,448	4,401	4,364	4,795	4,698	4,781	4,814	4,769
Goodwill	3,297	3,298	3,281	3,306	3,292	3,291	3,443	3,423	3,624	3,644	3,645
Intangible Assets	1,202	940	889	833	752	688	845	793	674	642	547
Other Noncurrent Operating Assets	240	267	268	310	357	386	411	434	483	528	577
Total Liabilities & Shareholders' Equity	9,449	9,338	9,139	8,470	8,714	8,890	9,156	8,729	8,545	8,806	9,181
Total Liabilities	4,148	4,156	4,122	3,816	3,870	3,939	4,026	3,955	3,926	3,964	3,936
Total Current Liabilities	955	981	1,207	899	955	1,002	1,037	1,002	990	963	951
Short-Term Debt	26	32	287	37	37	38	38	47	56	0.00	5.80
Accounts Payable	187	181	175	184	203	202	204	237	209	193	201
Accrued Expenses	508	533	535	484	504	541	580	528	508	554	570
Current Deferred Revenue	231	233	199	191	208	219	213	188	213	213	171
Other Current Liabilities	2.90	2.90	3.10	3.20	3.20	3.20	3.30	3.30	3.30	3.40	3.50
Total Noncurrent Liabilities	3,193	3,175	2,915	2,917	2,915	2,937	2,989	2,953	2,937	3,001	2,984
Long-Term Debt	2,798	2,789	2,531	2,523	2,514	2,506	2,497	2,479	2,461	2,509	2,503
Capital Lease Obligations	17	16	15	15	14	13	12	11	10	10	8.10
Noncurrent Deferred Revenue	13	14	14	14	15	15	14	12	12	12	12
Noncurrent Deferred & Payable Income Tax Liabilities	33	19	20	20	18	18	59	54	47	47	42
Other Noncurrent Operating Liabilities	332	336	335	345	354	386	406	397	406	423	419
Total Equity & Noncontrolling Interests	5,301	5,182	5,017	4,654	4,844	4,951	5,130	4,773	4,619	4,843	5,245
Total Preferred & Common Equity	5,301	5,182	5,017	4,654	4,844	4,951	5,130	4,773	4,619	4,843	5,245
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	5,301	5,182	5,017	4,654	4,844	4,951	5,130	4,773	4,619	4,843	5,245
Common Stock	6,095	6,126	6,144	6,062	6,201	6,216	6,247	6,262	6,305	6,320	6,361
Retained Earnings	2,006	1,966	2,056	2,303	2,473	2,667	2,846	3,047	3,029	3,224	3,591
Treasury Stock	-2,682	-2,796	-3,036	-3,592	-3,692	-3,793	-3,852	-4,373	-4,575	-4,611	-4,611
Accumulated Other Comprehensive Income / (Loss)	-118	-114	-148	-119	-137	-140	-112	-163	-140	-90	-95

This table displays calculated financial ratios and metrics derived from Hologic's official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	9/26/2015	9/24/2016	9/30/2017	9/29/2018	9/28/2019	9/26/2020	9/25/2021	9/24/2022	9/30/2023	9/28/2024	9/27/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	6.89%	4.72%	7.98%	0.00%	4.64%	12.15%	49.14%	-13.66%	-17.12%	0.00%	1.74%
EBITDA Growth	15.30%	9.35%	72.21%	-86.71%	36.96%	335.19%	93.40%	-27.09%	-52.88%	19.94%	-13.79%
EBIT Growth	61.61%	29.52%	140.46%	-116.65%	47.59%	1,023.03%	122.14%	-32.48%	-60.10%	31.77%	-17.60%
NOPAT Growth	235.97%	29.29%	92.52%	-119.80%	47.96%	1,513.31%	60.36%	-31.54%	-66.47%	78.67%	-26.36%
Net Income Growth	660.69%	151.37%	128.39%	-114.73%	-82.93%	645.43%	68.37%	-30.36%	-64.98%	73.14%	-28.35%
EPS Growth	650.00%	157.78%	127.59%	-115.15%	-90.00%	653.95%	71.26%	-28.85%	-64.33%	81.42%	-25.00%
Operating Cash Flow Growth	56.73%	0.18%	-98.96%	8,730.12%	-11.38%	38.04%	159.92%	-8.78%	-50.55%	22.26%	-17.75%
Free Cash Flow Firm Growth	70.78%	-4.45%	-72.75%	77.03%	22.83%	86.59%	18.62%	125.97%	-66.41%	0.28%	-31.22%
Invested Capital Growth	-6.99%	-4.98%	13.19%	-8.98%	-9.81%	9.92%	20.84%	-11.78%	-4.50%	2.16%	2.20%
Revenue Q/Q Growth	1.58%	0.85%	2.55%	0.00%	1.58%	14.60%	-0.54%	-6.95%	-0.20%	1.07%	1.53%
EBITDA Q/Q Growth	1.25%	2.17%	-1.80%	-10.68%	-35.13%	91.46%	-6.04%	-11.97%	-4.96%	7.85%	1.66%
EBIT Q/Q Growth	5.61%	5.87%	-2.65%	-2.17%	-267.41%	190.74%	-7.78%	-14.11%	-3.00%	11.03%	1.66%
NOPAT Q/Q Growth	13.51%	4.68%	-1.12%	-4.53%	-300.65%	68.61%	-7.29%	-14.90%	-7.26%	15.41%	1.69%
Net Income Q/Q Growth	-2.16%	25.40%	-1.24%	-40.71%	-587.84%	125.03%	-8.10%	-13.89%	-5.80%	12.54%	1.54%
EPS Q/Q Growth	-4.26%	27.47%	-1.49%	-29.03%	-660.00%	126.34%	-7.68%	-13.64%	-5.67%	12.93%	3.75%
Operating Cash Flow Q/Q Growth	16.27%	-1.81%	-88.18%	9.86%	2.41%	27.67%	1.01%	-12.25%	9.37%	9.20%	-1.11%
Free Cash Flow Firm Q/Q Growth	8.62%	1.66%	-46.01%	53.12%	27.34%	1.38%	20.34%	-10.59%	-0.37%	-21.45%	183.41%
Invested Capital Q/Q Growth	-1.74%	-1.67%	1.24%	-1.08%	-5.63%	4.43%	-1.53%	-1.56%	-2.25%	3.53%	-2.20%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	52.96%	55.19%	52.99%	52.73%	34.77%	58.98%	67.39%	61.64%	51.40%	55.28%	51.65%
EBITDA Margin	36.94%	38.57%	61.52%	7.77%	10.17%	39.46%	51.17%	43.21%	24.57%	29.46%	24.97%
Operating Margin	16.82%	19.37%	44.80%	-7.39%	-3.68%	29.26%	44.04%	33.73%	16.58%	21.90%	17.42%
EBIT Margin	16.42%	20.31%	45.22%	-7.16%	-3.58%	29.50%	43.94%	34.37%	16.54%	21.80%	17.65%
Profit (Net Income) Margin	4.87%	11.68%	24.70%	-3.46%	-6.05%	29.41%	33.20%	26.77%	11.31%	19.59%	13.80%
Tax Burden Percent	74.27%	79.65%	61.40%	26.59%	79.01%	110.84%	79.19%	81.98%	67.45%	91.26%	83.04%
Interest Burden Percent	39.90%	72.20%	88.97%	181.76%	213.50%	89.93%	95.40%	95.04%	101.41%	98.47%	94.10%
Effective Tax Rate	25.73%	20.35%	38.60%	0.00%	0.00%	-10.84%	20.81%	18.02%	32.55%	8.74%	16.96%
Return on Invested Capital (ROIC)	6.27%	8.62%	15.98%	-3.12%	-1.79%	25.42%	35.26%	23.44%	8.58%	15.52%	11.18%
ROIC Less NNEP Spread (ROIC-NNEP)	0.05%	5.03%	12.92%	-1.10%	-6.35%	20.67%	30.78%	19.85%	10.25%	1.98%	-1.57%
Return on Net Nonoperating Assets (RNNOA)	0.09%	7.05%	14.69%	-1.15%	-7.17%	20.63%	18.73%	5.19%	0.64%	0.05%	-0.07%
Return on Equity (ROE)	6.35%	15.67%	30.67%	-4.27%	-8.96%	46.05%	53.99%	28.63%	9.22%	15.56%	11.12%
Cash Return on Invested Capital (CROIC)	13.50%	13.73%	3.60%	6.29%	8.52%	15.97%	16.39%	35.96%	13.18%	13.38%	9.01%
Operating Return on Assets (OROA)	5.53%	7.69%	18.08%	-3.03%	-1.77%	16.34%	30.71%	18.58%	7.32%	9.60%	7.97%
Return on Assets (ROA)	1.64%	4.42%	9.88%	-1.46%	-2.98%	16.29%	23.20%	14.47%	5.01%	8.63%	6.23%
Return on Common Equity (ROCE)	6.35%	15.67%	30.67%	-4.27%	-8.96%	46.03%	53.98%	28.63%	9.22%	15.56%	11.12%
Return on Equity Simple (ROE_SIMPLE)	6.33%	15.44%	27.13%	-4.58%	-9.62%	41.05%	44.32%	26.70%	9.09%	15.39%	0.00%
Net Operating Profit after Tax (NOPAT)	338	437	841	-167	-87	1,225	1,964	1,345	451	805	593
NOPAT Margin	12.49%	15.43%	27.50%	-5.18%	-2.57%	32.43%	34.87%	27.65%	11.19%	19.99%	14.47%
Net Nonoperating Expense Percent (NNEP)	6.21%	3.59%	3.06%	-2.02%	4.56%	4.75%	4.48%	3.58%	-1.67%	13.53%	12.76%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	-	-	7.84%
Cost of Revenue to Revenue	47.04%	37.62%	47.01%	47.27%	65.23%	41.02%	32.61%	38.36%	48.60%	44.72%	48.35%
SG&A Expenses to Revenue	9.65%	9.44%	11.22%	11.38%	9.87%	9.42%	7.69%	8.38%	9.74%	10.16%	10.96%
R&D to Revenue	7.94%	8.19%	7.61%	6.80%	6.90%	5.89%	4.91%	5.83%	7.30%	6.77%	6.05%
Operating Expenses to Revenue	36.14%	43.01%	8.20%	60.12%	38.45%	29.72%	23.36%	27.91%	34.81%	33.38%	34.23%
Earnings before Interest and Taxes (EBIT)	444	575	1,383	-230	-121	1,114	2,475	1,671	667	879	724
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	999	1,093	1,882	250	342	1,490	2,882	2,101	990	1,188	1,024
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	5.42	4.98	3.76	4.59	6.27	6.16	4.60	3.22	3.39	3.66	2.96
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	43.78	20.07	22.29	18.27
Price to Revenue (P/Rev)	4.17	3.77	3.43	3.47	3.94	4.41	3.44	3.23	4.22	4.66	3.65
Price to Earnings (P/E)	85.65	32.25	13.87	0.00	0.00	14.94	10.36	12.08	37.28	23.78	26.43
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	1.17%	3.10%	7.21%	0.00%	0.00%	6.69%	9.65%	8.28%	2.68%	4.21%	3.78%
Enterprise Value to Invested Capital (EV/IC)	2.77	2.73	2.38	2.71	3.43	3.77	3.68	3.45	3.33	3.60	2.85
Enterprise Value to Revenue (EV/Rev)	5.32	4.75	4.34	4.29	4.67	5.03	3.98	3.82	4.25	4.69	3.72
Enterprise Value to EBITDA (EV/EBITDA)	14.40	12.32	7.06	55.25	45.96	12.75	7.79	8.84	17.28	15.91	14.91
Enterprise Value to EBIT (EV/EBIT)	32.41	23.41	9.61	0.00	0.00	17.06	9.06	11.11	25.66	21.50	21.08
Enterprise Value to NOPAT (EV/NOPAT)	42.58	30.81	15.79	0.00	0.00	15.52	11.42	13.81	37.95	23.45	25.73
Enterprise Value to Operating Cash Flow (EV/OCF)	18.06	16.87	1,600.87	18.85	24.23	21.20	9.63	8.73	16.28	14.70	14.44
Enterprise Value to Free Cash Flow (EV/FCFF)	19.76	19.35	70.05	41.13	38.15	24.70	24.58	9.00	24.70	27.19	31.94
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.74	1.56	1.20	1.37	1.45	1.12	0.72	0.58	0.56	0.50	0.50
Long-Term Debt to Equity	1.55	1.42	0.79	1.12	1.32	1.00	0.65	0.58	0.51	0.49	0.50
Financial Leverage	1.60	1.40	1.14	1.05	1.13	1.00	0.61	0.26	0.06	0.02	0.04
Leverage Ratio	3.88	3.54	3.10	2.92	3.01	2.83	2.33	1.98	1.84	1.80	1.79
Compound Leverage Factor	1.55	2.56	2.76	5.30	6.42	2.54	2.22	1.88	1.87	1.78	1.68
Debt to Total Capital	63.47%	60.96%	54.59%	57.80%	59.25%	52.88%	41.95%	36.82%	36.09%	33.18%	33.27%
Short-Term Debt to Total Capital	6.87%	5.39%	18.79%	10.45%	5.26%	5.65%	4.31%	0.19%	3.66%	0.49%	0.04%
Long-Term Debt to Total Capital	56.59%	55.56%	35.79%	47.35%	53.99%	47.23%	37.64%	36.62%	32.44%	32.69%	33.23%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.04%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	36.53%	39.04%	45.41%	42.20%	40.75%	47.08%	58.05%	63.18%	63.91%	66.82%	66.73%
Debt to EBITDA	3.61	3.06	1.78	13.31	8.98	2.04	1.06	1.35	2.86	2.14	2.46
Net Debt to EBITDA	3.12	2.56	1.49	10.64	7.23	1.57	1.06	1.35	0.11	0.10	0.31
Long-Term Debt to EBITDA	3.22	2.79	1.17	10.90	8.19	1.82	0.95	1.35	2.57	2.11	2.46
Debt to NOPAT	10.69	7.66	3.98	-19.98	-35.50	2.48	1.55	2.11	6.29	3.16	4.24
Net Debt to NOPAT	9.23	6.40	3.34	-15.97	-28.55	1.91	1.55	2.11	0.25	0.15	0.53
Long-Term Debt to NOPAT	9.53	6.98	2.61	-16.37	-32.34	2.22	1.39	2.10	5.65	3.12	4.24
Altman Z-Score	1.18	1.35	1.69	1.30	1.85	3.12	4.32	4.03	3.86	4.35	3.87
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.04%	0.03%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.34	1.47	0.79	1.23	1.68	1.79	2.39	4.12	3.47	3.69	3.75
Quick Ratio	0.96	1.10	0.58	0.89	1.17	1.40	0.71	0.66	2.77	2.83	2.87
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	728	696	190	336	412	770	913	2,063	693	695	478
Operating Cash Flow to CapEx	891.28%	844.66%	7.71%	694.03%	595.33%	573.27%	1,311.42%	1,671.15%	699.87%	987.10%	771.61%
Free Cash Flow to Firm to Interest Expense	2.72	4.33	1.21	1.73	2.91	6.61	7.92	21.53	6.24	5.69	4.08
Operating Cash Flow to Interest Expense	2.97	4.97	0.05	3.77	4.59	7.70	20.23	22.19	9.46	10.53	9.03
Operating Cash Flow Less CapEx to Interest Expense	2.64	4.38	-0.63	3.22	3.82	6.35	18.69	20.86	8.11	9.46	7.86
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.34	0.38	0.40	0.42	0.49	0.55	0.70	0.54	0.44	0.44	0.45
Accounts Receivable Turnover	6.66	6.56	6.24	5.78	5.48	4.50	5.71	6.23	6.48	6.57	6.83
Inventory Turnover	4.15	3.82	4.74	4.25	5.30	3.69	4.10	3.32	3.16	2.78	2.92
Fixed Asset Turnover	5.89	6.18	6.56	6.77	7.10	7.85	10.67	9.30	8.07	7.64	7.47
Accounts Payable Turnover	12.17	7.78	8.89	8.48	11.60	8.48	9.31	9.02	10.51	9.51	9.98
Days Sales Outstanding (DSO)	54.79	55.61	58.50	63.11	66.55	81.07	63.88	58.56	56.29	55.52	53.46
Days Inventory Outstanding (DIO)	88.03	95.52	76.96	85.86	68.88	98.97	89.07	110.05	115.65	131.36	125.12
Days Payable Outstanding (DPO)	29.99	46.91	41.06	43.05	31.47	43.04	39.22	40.46	34.74	38.37	36.56
Cash Conversion Cycle (CCC)	112.83	104.22	94.40	105.92	103.97	137.00	113.73	128.15	137.20	148.50	142.01
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	5,199	4,940	5,591	5,089	4,590	5,045	6,096	5,378	5,136	5,247	5,362
Invested Capital Turnover	0.50	0.56	0.58	0.60	0.70	0.78	1.01	0.85	0.77	0.78	0.77
Increase / (Decrease) in Invested Capital	-390	-259	652	-502	-499	455	1,051	-718	-242	111	115
Enterprise Value (EV)	14,392	13,464	13,287	13,812	15,735	19,006	22,435	18,565	17,110	18,889	15,263
Market Capitalization	11,272	10,667	10,481	11,152	13,261	16,666	19,387	15,723	16,999	18,772	14,949
Book Value per Share	$7.38	$7.72	$9.75	$8.93	$7.91	$10.45	$16.64	$19.53	$20.48	$22.09	$22.70
Tangible Book Value per Share	($13.32)	($11.91)	($11.06)	($9.20)	($7.14)	($4.87)	($2.85)	$1.44	$3.46	$3.63	$3.68
Total Capital	5,691	5,488	6,132	5,756	5,192	5,746	7,267	7,718	7,850	7,677	7,565
Total Debt	3,612	3,345	3,347	3,327	3,076	3,039	3,048	2,841	2,834	2,547	2,517
Total Long-Term Debt	3,221	3,049	2,195	2,726	2,803	2,714	2,735	2,826	2,547	2,509	2,514
Net Debt	3,120	2,797	2,807	2,660	2,474	2,338	3,048	2,841	111	117	314
Capital Expenditures (CapEx)	89	95	108	106	109	156	178	127	150	130	137
Debt-free, Cash-free Net Working Capital (DFCFNWC)	221	172	225	255	394	607	2,155	2,939	542	490	491
Debt-free Net Working Capital (DFNWC)	714	721	766	922	996	1,308	2,155	2,939	3,264	2,824	2,694
Net Working Capital (NWC)	322	425	-387	321	723	983	1,842	2,924	2,977	2,786	2,691
Net Nonoperating Expense (NNE)	206	106	86	-55	117	114	94	43	-5.19	16	27
Net Nonoperating Obligations (NNO)	3,120	2,797	2,807	2,660	2,474	2,338	1,878	502	119	117	314
Total Depreciation and Amortization (D&A)	555	518	499	480	463	376	407	430	323	309	300
Debt-free, Cash-free Net Working Capital to Revenue	8.17%	6.08%	7.35%	7.93%	11.71%	16.07%	38.26%	60.44%	13.44%	12.16%	11.98%
Debt-free Net Working Capital to Revenue	26.38%	25.44%	25.03%	28.65%	29.58%	34.63%	38.26%	60.44%	80.99%	70.06%	65.69%
Net Working Capital to Revenue	11.92%	14.99%	-12.65%	9.96%	21.47%	26.03%	32.70%	60.14%	73.87%	69.13%	65.62%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.47	$1.18	$2.70	($0.40)	($0.76)	$4.24	$7.28	$5.18	$1.85	$3.35	$2.50
Adjusted Weighted Average Basic Shares Outstanding	280.57M	280.21M	279.81M	275.11M	269.41M	262.73M	257.05M	251.53M	246.77M	235.72M	226.16M
Adjusted Diluted Earnings per Share	$0.45	$1.16	$2.64	($0.40)	($0.76)	$4.21	$7.21	$5.13	$1.83	$3.32	$2.49
Adjusted Weighted Average Diluted Shares Outstanding	289.54M	286.16M	285.65M	275.11M	269.41M	264.61M	259.71M	253.85M	248.83M	237.55M	227.57M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	282.91M	278.22M	0.00	289.21M	268.15M	257.01M	251.42M	245.83M	240.00M	226.94M	222.91M
Normalized Net Operating Profit after Tax (NOPAT)	359	445	297	356	-7.35	787	1,971	1,369	524	848	652
Normalized NOPAT Margin	13.28%	15.72%	9.71%	11.05%	-0.22%	20.85%	35.00%	28.16%	12.99%	21.04%	15.91%
Pre Tax Income Margin	6.55%	14.66%	40.23%	-13.01%	-7.65%	26.53%	41.92%	32.66%	16.78%	21.46%	16.61%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	1.66	3.58	8.84	-1.18	-0.85	9.56	21.48	17.44	6.00	7.19	6.18
NOPAT to Interest Expense	1.26	2.72	5.38	-0.86	-0.61	10.51	17.05	14.04	4.06	6.60	5.07
EBIT Less CapEx to Interest Expense	1.32	2.99	8.16	-1.73	-1.62	8.22	19.94	16.12	4.65	6.13	5.01
NOPAT Less CapEx to Interest Expense	0.93	2.13	4.69	-1.40	-1.38	9.17	15.51	12.71	2.71	5.53	3.90
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.16%	0.45%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	75.57%	26.49%	-247.80%	-98.28%	59.02%	22.37%	41.64%	104.12%	105.78%	133.09%

This table displays calculated financial ratios and metrics derived from Hologic's official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	7/1/2023	9/30/2023	12/30/2023	3/30/2024	6/29/2024	9/28/2024	12/28/2024	3/29/2025	6/28/2025	9/27/2025	12/27/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-1.83%	-0.84%	-5.69%	-0.85%	2.74%	4.52%	0.86%	-1.23%	1.23%	6.23%	2.54%
EBITDA Growth	-76.59%	-19.51%	-16.45%	-17.51%	257.63%	40.51%	18.00%	-78.91%	0.35%	5.57%	-6.28%
EBIT Growth	-97.28%	-13.01%	-23.20%	-20.07%	3,245.21%	63.35%	34.00%	-106.51%	1.35%	5.24%	-6.38%
NOPAT Growth	-101.93%	-29.26%	24.18%	-20.60%	4,307.61%	124.83%	-26.93%	-102.90%	7.10%	5.30%	-0.98%
Net Income Growth	-117.73%	-23.67%	31.54%	-22.24%	580.25%	97.13%	-18.46%	-110.24%	0.21%	4.82%	-10.90%
EPS Growth	-117.78%	-22.92%	37.33%	-17.24%	612.50%	102.70%	-15.53%	-111.11%	4.88%	12.00%	-9.20%
Operating Cash Flow Growth	0.64%	53.44%	-13.18%	41.74%	21.94%	41.86%	-13.95%	-42.07%	-15.40%	-3.24%	21.45%
Free Cash Flow Firm Growth	-78.90%	-61.13%	-49.37%	103.71%	87.51%	-76.99%	-57.47%	-160.26%	-153.05%	6.99%	-59.97%
Invested Capital Growth	-3.83%	-4.50%	-3.62%	-5.93%	-3.55%	2.16%	-0.13%	5.65%	8.18%	2.20%	2.03%
Revenue Q/Q Growth	-4.10%	-3.97%	7.17%	0.46%	-0.63%	-2.31%	3.42%	-1.61%	1.84%	2.52%	-0.17%
EBITDA Q/Q Growth	-75.13%	141.02%	30.24%	5.65%	7.84%	-5.31%	9.38%	-81.12%	413.09%	-0.38%	-2.91%
EBIT Q/Q Growth	-97.35%	1,787.67%	37.45%	16.05%	11.10%	-7.82%	12.75%	-105.63%	1,830.77%	-4.28%	0.30%
NOPAT Q/Q Growth	-102.20%	1,859.48%	209.76%	-33.82%	16.66%	-5.98%	0.68%	-102.63%	4,409.30%	-7.56%	-5.33%
Net Income Q/Q Growth	-118.54%	323.70%	172.08%	-31.08%	14.48%	-8.17%	12.54%	-108.66%	1,220.11%	-3.95%	-4.33%
EPS Q/Q Growth	-118.39%	331.25%	178.38%	-30.10%	13.89%	-8.54%	16.00%	-109.20%	1,175.00%	-2.33%	-5.95%
Operating Cash Flow Q/Q Growth	61.32%	-22.27%	-14.96%	32.91%	38.78%	-9.56%	-48.42%	-10.51%	102.66%	3.44%	-35.26%
Free Cash Flow Firm Q/Q Growth	-16.44%	58.57%	40.11%	9.73%	-23.08%	-80.54%	158.91%	-255.49%	32.29%	139.25%	-3.13%
Invested Capital Q/Q Growth	-5.49%	-2.25%	3.12%	-1.26%	-3.10%	3.53%	0.82%	4.45%	-0.78%	-2.20%	0.65%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	37.33%	52.93%	56.02%	53.28%	55.40%	56.45%	56.81%	37.53%	56.32%	55.59%	55.96%
EBITDA Margin	8.99%	22.56%	27.42%	28.84%	31.29%	30.33%	32.08%	6.16%	31.02%	30.14%	29.32%
Operating Margin	0.14%	14.02%	19.56%	20.67%	24.13%	23.28%	22.49%	-0.70%	24.87%	22.57%	22.62%
EBIT Margin	0.74%	14.58%	18.70%	21.60%	24.14%	22.78%	24.84%	-1.42%	24.17%	22.57%	22.68%
Profit (Net Income) Margin	-4.11%	9.58%	24.33%	16.69%	19.23%	18.08%	19.67%	-1.73%	19.04%	17.84%	17.09%
Tax Burden Percent	-334.71%	62.23%	128.86%	80.33%	80.81%	80.60%	81.21%	61.05%	82.94%	82.39%	77.97%
Interest Burden Percent	165.75%	105.66%	101.00%	96.22%	98.57%	98.45%	97.52%	199.30%	94.95%	95.91%	96.68%
Effective Tax Rate	434.71%	37.77%	-28.86%	19.67%	19.19%	19.40%	18.79%	0.00%	17.06%	17.61%	22.03%
Return on Invested Capital (ROIC)	-0.36%	6.69%	18.54%	12.19%	15.06%	14.57%	13.94%	-0.37%	15.79%	14.38%	13.62%
ROIC Less NNEP Spread (ROIC-NNEP)	-13.67%	9.31%	16.84%	12.47%	12.24%	8.83%	16.42%	-2.30%	11.50%	10.67%	11.92%
Return on Net Nonoperating Assets (RNNOA)	-0.72%	0.58%	1.81%	0.79%	0.23%	0.21%	2.02%	-0.31%	0.89%	0.45%	0.80%
Return on Equity (ROE)	-1.08%	7.27%	20.35%	12.98%	15.29%	14.77%	15.96%	-0.68%	16.68%	14.83%	14.41%
Cash Return on Invested Capital (CROIC)	12.98%	13.18%	12.87%	14.48%	17.14%	13.38%	14.07%	5.09%	3.20%	9.01%	9.06%
Operating Return on Assets (OROA)	0.32%	6.45%	8.36%	9.42%	10.56%	10.04%	11.67%	-0.66%	11.04%	10.19%	10.45%
Return on Assets (ROA)	-1.78%	4.24%	10.88%	7.28%	8.41%	7.96%	9.24%	-0.81%	8.69%	8.05%	7.88%
Return on Common Equity (ROCE)	-1.08%	7.27%	20.35%	12.98%	15.29%	14.77%	15.96%	-0.68%	16.68%	14.83%	14.41%
Return on Equity Simple (ROE_SIMPLE)	9.34%	0.00%	11.07%	9.63%	14.17%	0.00%	15.59%	12.05%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-4.69	82	255	169	197	185	187	-4.90	211	195	185
NOPAT Margin	-0.48%	8.72%	25.21%	16.61%	19.49%	18.76%	18.26%	-0.49%	20.62%	18.60%	17.64%
Net Nonoperating Expense Percent (NNEP)	13.31%	-2.62%	1.70%	-0.27%	2.82%	5.74%	-2.48%	1.94%	4.30%	3.71%	1.70%
Return On Investment Capital (ROIC_SIMPLE)	-	-	3.53%	-	-	-	2.55%	-0.07%	2.87%	2.58%	2.38%
Cost of Revenue to Revenue	62.67%	47.08%	43.98%	46.72%	44.60%	43.55%	43.19%	62.47%	43.68%	44.41%	44.04%
SG&A Expenses to Revenue	9.16%	9.83%	11.04%	9.86%	9.29%	10.45%	11.32%	11.91%	9.68%	10.94%	12.20%
R&D to Revenue	7.38%	7.71%	6.59%	7.33%	6.34%	6.81%	5.90%	6.12%	6.00%	6.19%	5.77%
Operating Expenses to Revenue	37.19%	38.91%	36.45%	32.61%	31.27%	33.17%	34.32%	38.23%	31.45%	33.02%	33.35%
Earnings before Interest and Taxes (EBIT)	7.30	138	189	220	244	225	254	-14	248	237	238
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	89	213	278	294	317	300	328	62	318	316	307
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.85	3.39	3.76	3.78	3.50	3.66	3.45	2.98	2.99	2.96	3.17
Price to Tangible Book Value (P/TBV)	21.12	20.07	33.97	22.87	17.82	22.29	29.57	42.88	26.04	18.27	15.78
Price to Revenue (P/Rev)	4.93	4.22	4.41	4.62	4.35	4.66	4.08	3.42	3.59	3.65	4.02
Price to Earnings (P/E)	41.17	37.28	33.98	39.23	24.70	23.78	22.15	24.72	26.00	26.43	30.54
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	2.43%	2.68%	2.94%	2.55%	4.05%	4.21%	4.52%	4.05%	3.85%	3.78%	3.27%
Enterprise Value to Invested Capital (EV/IC)	3.81	3.33	3.43	3.57	3.44	3.60	3.21	2.65	2.76	2.85	3.11
Enterprise Value to Revenue (EV/Rev)	4.95	4.25	4.57	4.72	4.37	4.69	4.21	3.64	3.75	3.72	4.06
Enterprise Value to EBITDA (EV/EBITDA)	19.20	17.28	19.40	21.40	15.84	15.91	13.73	14.58	15.02	14.91	16.71
Enterprise Value to EBIT (EV/EBIT)	29.10	25.66	29.77	33.71	22.05	21.50	18.02	20.69	21.24	21.08	23.68
Enterprise Value to NOPAT (EV/NOPAT)	41.14	37.95	36.63	41.38	25.00	23.45	23.02	25.76	25.93	25.73	28.34
Enterprise Value to Operating Cash Flow (EV/OCF)	20.81	16.28	17.83	16.93	14.82	14.70	13.55	12.96	14.15	14.44	15.27
Enterprise Value to Free Cash Flow (EV/FCFF)	28.76	24.70	26.12	23.91	19.72	27.19	22.81	53.59	89.71	31.94	34.62
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.55	0.56	0.55	0.53	0.52	0.50	0.53	0.55	0.52	0.50	0.48
Long-Term Debt to Equity	0.54	0.51	0.55	0.52	0.51	0.49	0.52	0.54	0.52	0.50	0.48
Financial Leverage	0.05	0.06	0.11	0.06	0.02	0.02	0.12	0.14	0.08	0.04	0.07
Leverage Ratio	1.84	1.84	1.82	1.79	1.80	1.80	1.82	1.82	1.81	1.79	1.79
Compound Leverage Factor	3.04	1.94	1.84	1.72	1.77	1.78	1.78	3.64	1.72	1.71	1.73
Debt to Total Capital	35.38%	36.09%	35.62%	34.62%	34.05%	33.18%	34.71%	35.37%	34.22%	33.27%	32.43%
Short-Term Debt to Total Capital	0.40%	3.66%	0.52%	0.50%	0.50%	0.49%	0.64%	0.79%	0.00%	0.04%	0.07%
Long-Term Debt to Total Capital	34.98%	32.44%	35.10%	34.12%	33.55%	32.69%	34.07%	34.58%	34.22%	33.23%	32.35%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	64.62%	63.91%	64.38%	65.38%	65.95%	66.82%	65.29%	64.63%	65.78%	66.73%	67.57%
Debt to EBITDA	2.72	2.86	2.75	2.94	2.32	2.14	2.05	2.51	2.50	2.46	2.51
Net Debt to EBITDA	0.07	0.11	0.69	0.44	0.11	0.10	0.42	0.90	0.64	0.31	0.15
Long-Term Debt to EBITDA	2.69	2.57	2.71	2.90	2.29	2.11	2.01	2.46	2.50	2.46	2.50
Debt to NOPAT	5.84	6.29	5.20	5.68	3.66	3.16	3.44	4.44	4.32	4.24	4.26
Net Debt to NOPAT	0.15	0.25	1.30	0.85	0.17	0.15	0.70	1.59	1.10	0.53	0.26
Long-Term Debt to NOPAT	5.77	5.65	5.12	5.60	3.61	3.12	3.37	4.34	4.32	4.24	4.25
Altman Z-Score	4.04	3.67	4.04	4.16	4.00	4.12	3.89	3.38	3.59	3.69	3.99
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.42	3.47	3.89	3.97	3.99	3.69	3.49	3.24	3.55	3.75	4.04
Quick Ratio	3.52	2.77	2.90	2.96	3.06	2.83	2.60	2.29	2.59	2.87	3.10
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	205	324	455	499	384	75	193	-301	-204	80	77
Operating Cash Flow to CapEx	911.78%	492.76%	578.95%	1,044.29%	1,197.05%	1,211.22%	599.05%	421.39%	986.49%	1,168.09%	654.99%
Free Cash Flow to Firm to Interest Expense	7.39	11.55	17.48	15.44	12.03	2.34	6.34	-10.33	-7.04	2.79	2.80
Operating Cash Flow to Interest Expense	12.01	9.21	8.46	9.05	12.72	11.50	6.21	5.82	11.88	12.42	8.33
Operating Cash Flow Less CapEx to Interest Expense	10.70	7.34	7.00	8.19	11.66	10.55	5.17	4.44	10.67	11.35	7.06
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.43	0.44	0.45	0.44	0.44	0.44	0.47	0.47	0.46	0.45	0.46
Accounts Receivable Turnover	5.81	6.48	5.90	5.82	6.06	6.57	6.20	6.24	6.53	6.83	6.79
Inventory Turnover	3.10	3.16	2.97	2.97	2.70	2.78	2.68	2.86	2.82	2.92	2.87
Fixed Asset Turnover	8.21	8.07	7.77	7.75	7.80	7.64	7.59	7.45	7.35	7.47	7.47
Accounts Payable Turnover	9.83	10.51	10.10	10.17	9.50	9.51	8.55	9.49	9.86	9.98	9.15
Days Sales Outstanding (DSO)	62.80	56.29	61.83	62.72	60.20	55.52	58.84	58.54	55.93	53.46	53.76
Days Inventory Outstanding (DIO)	117.89	115.65	122.84	123.03	135.14	131.36	136.07	127.79	129.29	125.12	127.18
Days Payable Outstanding (DPO)	37.13	34.74	36.12	35.88	38.42	38.37	42.68	38.46	37.00	36.56	39.90
Cash Conversion Cycle (CCC)	143.57	137.20	148.54	149.86	156.91	148.50	152.24	147.86	148.22	142.01	141.04
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	5,254	5,136	5,297	5,230	5,068	5,247	5,290	5,525	5,483	5,362	5,397
Invested Capital Turnover	0.75	0.77	0.74	0.73	0.77	0.78	0.76	0.75	0.77	0.77	0.77
Increase / (Decrease) in Invested Capital	-209	-242	-199	-330	-187	111	-6.70	296	415	115	107
Enterprise Value (EV)	20,000	17,110	18,144	18,685	17,445	18,889	16,992	14,666	15,127	15,263	16,759
Market Capitalization	19,928	16,999	17,501	18,300	17,328	18,772	16,476	13,760	14,487	14,949	16,606
Book Value per Share	$21.05	$20.48	$19.50	$20.64	$21.21	$22.09	$21.03	$20.58	$21.73	$22.70	$23.53
Tangible Book Value per Share	$3.83	$3.46	$2.16	$3.41	$4.17	$3.63	$2.45	$1.43	$2.50	$3.68	$4.72
Total Capital	8,019	7,850	7,229	7,410	7,507	7,677	7,310	7,146	7,362	7,565	7,762
Total Debt	2,837	2,834	2,575	2,565	2,556	2,547	2,537	2,528	2,519	2,517	2,517
Total Long-Term Debt	2,806	2,547	2,537	2,528	2,519	2,509	2,490	2,472	2,519	2,514	2,511
Net Debt	72	111	643	385	117	117	517	907	640	314	152
Capital Expenditures (CapEx)	37	53	38	28	34	30	32	40	35	30	35
Debt-free, Cash-free Net Working Capital (DFCFNWC)	625	542	701	692	593	490	565	654	580	491	533
Debt-free Net Working Capital (DFNWC)	3,390	3,264	2,633	2,872	3,032	2,824	2,538	2,275	2,459	2,694	2,898
Net Working Capital (NWC)	3,358	2,977	2,595	2,834	2,995	2,786	2,491	2,219	2,459	2,691	2,892
Net Nonoperating Expense (NNE)	36	-8.15	8.89	-0.88	2.67	6.77	-14	13	16	7.99	5.69
Net Nonoperating Obligations (NNO)	72	119	643	385	117	117	517	907	640	314	152
Total Depreciation and Amortization (D&A)	81	76	88	74	72	75	74	76	70	80	70
Debt-free, Cash-free Net Working Capital to Revenue	15.47%	13.44%	17.65%	17.46%	14.87%	12.16%	14.00%	16.25%	14.36%	11.98%	12.92%
Debt-free Net Working Capital to Revenue	83.94%	80.99%	66.32%	72.50%	76.04%	70.06%	62.84%	56.51%	60.88%	65.69%	70.23%
Net Working Capital to Revenue	83.15%	73.87%	65.38%	71.56%	75.10%	69.13%	61.68%	55.11%	60.88%	65.62%	70.09%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.16)	$0.37	$1.03	$0.72	$0.83	$0.77	$0.87	($0.08)	$0.87	$0.84	$0.80
Adjusted Weighted Average Basic Shares Outstanding	246.91M	246.77M	238.63M	235.89M	234.60M	235.72M	230.28M	225.77M	224.32M	226.16M	224.41M
Adjusted Diluted Earnings per Share	($0.16)	$0.37	$1.03	$0.72	$0.82	$0.75	$0.87	($0.08)	$0.86	$0.84	$0.79
Adjusted Weighted Average Diluted Shares Outstanding	246.91M	248.83M	240.21M	237.56M	236.47M	237.55M	232.11M	225.77M	225.46M	227.57M	225.88M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	244.94M	240.00M	234.73M	233.38M	232.27M	226.94M	224.39M	222.85M	222.42M	222.91M	223.24M
Normalized Net Operating Profit after Tax (NOPAT)	33	87	158	175	202	190	190	27	216	208	188
Normalized NOPAT Margin	3.40%	9.18%	15.55%	17.16%	20.02%	19.28%	18.57%	2.64%	21.14%	19.85%	17.93%
Pre Tax Income Margin	1.23%	15.40%	18.88%	20.78%	23.80%	22.43%	24.22%	-2.84%	22.95%	21.65%	21.92%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.26	4.90	7.28	6.81	7.66	7.06	8.32	-0.49	8.56	8.28	8.61
NOPAT to Interest Expense	-0.17	2.93	9.82	5.23	6.18	5.81	6.12	-0.17	7.31	6.82	6.70
EBIT Less CapEx to Interest Expense	-1.05	3.04	5.82	5.94	6.59	6.11	7.29	-1.87	7.36	7.22	7.34
NOPAT Less CapEx to Interest Expense	-1.49	1.07	8.36	4.37	5.12	4.86	5.08	-1.55	6.10	5.76	5.42
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	90.62%	104.12%	204.15%	214.71%	140.84%	105.78%	90.81%	157.28%	145.61%	133.09%	43.32%

Financials Breakdown Chart

Key Financial Trends

Here’s MarketBeat’s concise read on HOLOGIC INC (HOLX) using the latest four years of quarterly cash flow, income statement, and balance sheet data. The company shows strong cash generation and solid liquidity, with profitability generally positive across most quarters. Occasional softer quarters and a sizable treasury stock position are notable risks to monitor.

Key observations to consider for retail investors:

Robust operating cash flow across most quarters. Net cash from continuing operating activities has been positive in the majority of quarters (for example, Q4 2025: 355.1m; Q3 2025: 343.3m; Q1 2026: 229.9m), underscoring strong core cash generation.
Strong liquidity position. Cash & equivalents around $2.0B+ (e.g., Q1 2026 shows 2.168B) and Total current assets near $3.8B–$3.9B versus Total current liabilities near $0.95B, implying a solid liquidity cushion.
High gross margins with consistent profitability in many periods. Gross margins commonly mid-50s% (e.g., Q1 2026 gross margin ≈ 56%), and net income is positive in most quarters (e.g., Q4 2025: 187.2m; Q3 2025: 194.9m; Q1 2026: 179.1m).
Free cash flow generation from operations after capex is typically positive. After capex (purchase of property, plant & equipment) and other investing activity, cash flow from operations generally supports a healthy free cash flow profile in many quarters.
Debt service appears manageable with solid coverage. Interest expense runs in the $25–30m range while operating income runs higher, suggesting a comfortable cushion for debt service in many periods.
Occasional equity activity and investing activity are modestly variable. The company reports periodic issuance of common equity (e.g., Q1 2026: 8.3m inflow) and ongoing investing activity, which is typical for a growing firm but adds some financing/allocations to monitor.
Investing activities mainly reflect routine capex and modest acquisitions. Net cash used in investing varies but is generally modest relative to operating cash flow.
Healthy balance sheet but meaningful leverage persists. Long-term debt typically sits around $2.5B–$2.9B over several quarters, maintaining a leverage profile that is high but historically manageable given cash flow.
One quarterly net loss observed in the period (Q2 2025). Net income fluctuates, and Q2 2025 shows a negative bottom line before rebounding in subsequent quarters.
Treasury stock balance is substantial and reduces equity value. Treasury stock positions are large and negative, reducing total equity and potentially affecting per-share metrics.
Debt load could weigh on future equity value and interest obligations. While cash flow supports serviceability, the sizable long-term debt (~$2.5B–$2.9B across periods) introduces ongoing interest and principal commitments that investors should watch.

05/25/26 01:11 AM ETAI Generated. May Contain Errors.

Hologic Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Hologic's fiscal year ends in September. Their fiscal year 2025 ended on September 27, 2025.

Hologic's net income appears to be on an upward trend, with a most recent value of $565.70 million in 2025, rising from $131.60 million in 2015. The previous period was $789.50 million in 2024. Find out what analysts predict for Hologic in the coming months.

Hologic's total operating income in 2025 was $714.30 million, based on the following breakdown:

Total Gross Profit: $2.12 billion
Total Operating Expenses: $1.40 billion

Over the last 10 years, Hologic's total revenue changed from $2.71 billion in 2015 to $4.10 billion in 2025, a change of 51.6%.

Hologic's total liabilities were at $3.97 billion at the end of 2025, a 1.5% decrease from 2024, and a 28.7% decrease since 2015.

In the past 10 years, Hologic's cash and equivalents has ranged from $0.00 in 2021 to $2.72 billion in 2023, and is currently $1.96 billion as of their latest financial filing in 2025.

Over the last 10 years, Hologic's book value per share changed from 7.38 in 2015 to 22.70 in 2025, a change of 207.6%.

Related Companies

Financial statements for NASDAQ:HOLX last updated on 2/1/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hologic (HOLX) Financials

Financials Breakdown Chart

Key Financial Trends

Hologic Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Hologic (HOLX) Financials

Annual Income Statements for Hologic

Quarterly Income Statements for Hologic

Annual Cash Flow Statements for Hologic

Quarterly Cash Flow Statements for Hologic

Annual Balance Sheets for Hologic

Quarterly Balance Sheets for Hologic

Annual Metrics And Ratios for Hologic

Quarterly Metrics And Ratios for Hologic

Financials Breakdown Chart

Key Financial Trends

Hologic Financials - Frequently Asked Questions

When does Hologic's financial year end?

How has Hologic's net income changed over the last 10 years?

What is Hologic's operating income?

How has Hologic's revenue changed over the last 10 years?

How much debt does Hologic have?

How much cash does Hologic have?

How has Hologic's book value per share changed over the last 10 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools